Determination of unbound etoposide concentration in ultrafiltered plasma by high-performance liquid chromatography with fluorimetric detection

I. Robieux, P. Aita, R. Sorio, G. Toffoli, M. Boiocchi

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Etoposide is a highly protein bound drug, and monitoring the concentration of free drug could help individualize dosage in oncological patients. The cost and difficulty of the standard techniques (equilibration dialysis) has hampered the monitoring of free drugs. We describe a simple HPLC method for the measurement of free etoposide concentration in plasma. Sample preparation involves the ultrafiltration of plasma by a Centrifree device for 30 min at 2000 g and extraction with chloroform. The isocratic separation is performed with a μ Bondapak phenyl analytical column. Fluorimetric detection is used (288-328 nm excitation and emission wavelengths). Linearity of the calibration curve is excellent between 0.05 and 1 μg/ml. Accuracy and precision are reported at the concentrations 0.06 and 0.4 μg/ml: within-run accuracy is 10% and 6.2%, respectively; between-run accuracy is ≤1%; within-run coefficients of variation (C.V.) are 10.6 and 5.0%; between-run C.V. are 11.6 and 6.8% respectively. The range of the assay is 0.05 to 1 μg/ml. The feasibility of the technique has been tested in 7 patients treated with oral etoposide for hepatocarcinoma (mean protein binding 91%). We found no interference from endogenous substances, co-administered drugs (alizapride, furosemide, ranitidine) and other antineoplastic agents (doxorubicine, idarubicine, vinblastine, vinorelbine).

Original languageEnglish
Pages (from-to)35-41
Number of pages7
JournalJournal of Chromatography B: Biomedical Applications
Volume686
Issue number1
DOIs
Publication statusPublished - Nov 8 1996

Fingerprint

High performance liquid chromatography
Etoposide
Plasmas
Pharmaceutical Preparations
Ranitidine
Dialysis
Vinblastine
Monitoring
Furosemide
Ultrafiltration
Chloroform
Antineoplastic Agents
Assays
Calibration
Wavelength
Costs
Proteins

Keywords

  • Etoposide

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

@article{77ae0204961b4e218226ed3cce4dff01,
title = "Determination of unbound etoposide concentration in ultrafiltered plasma by high-performance liquid chromatography with fluorimetric detection",
abstract = "Etoposide is a highly protein bound drug, and monitoring the concentration of free drug could help individualize dosage in oncological patients. The cost and difficulty of the standard techniques (equilibration dialysis) has hampered the monitoring of free drugs. We describe a simple HPLC method for the measurement of free etoposide concentration in plasma. Sample preparation involves the ultrafiltration of plasma by a Centrifree device for 30 min at 2000 g and extraction with chloroform. The isocratic separation is performed with a μ Bondapak phenyl analytical column. Fluorimetric detection is used (288-328 nm excitation and emission wavelengths). Linearity of the calibration curve is excellent between 0.05 and 1 μg/ml. Accuracy and precision are reported at the concentrations 0.06 and 0.4 μg/ml: within-run accuracy is 10{\%} and 6.2{\%}, respectively; between-run accuracy is ≤1{\%}; within-run coefficients of variation (C.V.) are 10.6 and 5.0{\%}; between-run C.V. are 11.6 and 6.8{\%} respectively. The range of the assay is 0.05 to 1 μg/ml. The feasibility of the technique has been tested in 7 patients treated with oral etoposide for hepatocarcinoma (mean protein binding 91{\%}). We found no interference from endogenous substances, co-administered drugs (alizapride, furosemide, ranitidine) and other antineoplastic agents (doxorubicine, idarubicine, vinblastine, vinorelbine).",
keywords = "Etoposide",
author = "I. Robieux and P. Aita and R. Sorio and G. Toffoli and M. Boiocchi",
year = "1996",
month = "11",
day = "8",
doi = "10.1016/S0378-4347(96)00300-3",
language = "English",
volume = "686",
pages = "35--41",
journal = "Journal of Chromatography B: Biomedical Sciences and Applications",
issn = "1387-2273",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Determination of unbound etoposide concentration in ultrafiltered plasma by high-performance liquid chromatography with fluorimetric detection

AU - Robieux, I.

AU - Aita, P.

AU - Sorio, R.

AU - Toffoli, G.

AU - Boiocchi, M.

PY - 1996/11/8

Y1 - 1996/11/8

N2 - Etoposide is a highly protein bound drug, and monitoring the concentration of free drug could help individualize dosage in oncological patients. The cost and difficulty of the standard techniques (equilibration dialysis) has hampered the monitoring of free drugs. We describe a simple HPLC method for the measurement of free etoposide concentration in plasma. Sample preparation involves the ultrafiltration of plasma by a Centrifree device for 30 min at 2000 g and extraction with chloroform. The isocratic separation is performed with a μ Bondapak phenyl analytical column. Fluorimetric detection is used (288-328 nm excitation and emission wavelengths). Linearity of the calibration curve is excellent between 0.05 and 1 μg/ml. Accuracy and precision are reported at the concentrations 0.06 and 0.4 μg/ml: within-run accuracy is 10% and 6.2%, respectively; between-run accuracy is ≤1%; within-run coefficients of variation (C.V.) are 10.6 and 5.0%; between-run C.V. are 11.6 and 6.8% respectively. The range of the assay is 0.05 to 1 μg/ml. The feasibility of the technique has been tested in 7 patients treated with oral etoposide for hepatocarcinoma (mean protein binding 91%). We found no interference from endogenous substances, co-administered drugs (alizapride, furosemide, ranitidine) and other antineoplastic agents (doxorubicine, idarubicine, vinblastine, vinorelbine).

AB - Etoposide is a highly protein bound drug, and monitoring the concentration of free drug could help individualize dosage in oncological patients. The cost and difficulty of the standard techniques (equilibration dialysis) has hampered the monitoring of free drugs. We describe a simple HPLC method for the measurement of free etoposide concentration in plasma. Sample preparation involves the ultrafiltration of plasma by a Centrifree device for 30 min at 2000 g and extraction with chloroform. The isocratic separation is performed with a μ Bondapak phenyl analytical column. Fluorimetric detection is used (288-328 nm excitation and emission wavelengths). Linearity of the calibration curve is excellent between 0.05 and 1 μg/ml. Accuracy and precision are reported at the concentrations 0.06 and 0.4 μg/ml: within-run accuracy is 10% and 6.2%, respectively; between-run accuracy is ≤1%; within-run coefficients of variation (C.V.) are 10.6 and 5.0%; between-run C.V. are 11.6 and 6.8% respectively. The range of the assay is 0.05 to 1 μg/ml. The feasibility of the technique has been tested in 7 patients treated with oral etoposide for hepatocarcinoma (mean protein binding 91%). We found no interference from endogenous substances, co-administered drugs (alizapride, furosemide, ranitidine) and other antineoplastic agents (doxorubicine, idarubicine, vinblastine, vinorelbine).

KW - Etoposide

UR - http://www.scopus.com/inward/record.url?scp=0002040713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002040713&partnerID=8YFLogxK

U2 - 10.1016/S0378-4347(96)00300-3

DO - 10.1016/S0378-4347(96)00300-3

M3 - Article

C2 - 8953190

AN - SCOPUS:0002040713

VL - 686

SP - 35

EP - 41

JO - Journal of Chromatography B: Biomedical Sciences and Applications

JF - Journal of Chromatography B: Biomedical Sciences and Applications

SN - 1387-2273

IS - 1

ER -